AU2018329047B2 - Cycloolefin substituted heteroaromatic compounds and their use - Google Patents

Cycloolefin substituted heteroaromatic compounds and their use Download PDF

Info

Publication number
AU2018329047B2
AU2018329047B2 AU2018329047A AU2018329047A AU2018329047B2 AU 2018329047 B2 AU2018329047 B2 AU 2018329047B2 AU 2018329047 A AU2018329047 A AU 2018329047A AU 2018329047 A AU2018329047 A AU 2018329047A AU 2018329047 B2 AU2018329047 B2 AU 2018329047B2
Authority
AU
Australia
Prior art keywords
compound
formula
independently chosen
nmr
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018329047A
Other languages
English (en)
Other versions
AU2018329047A1 (en
Inventor
Guangxiu Dai
Wei-Guo Su
Kun Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of AU2018329047A1 publication Critical patent/AU2018329047A1/en
Application granted granted Critical
Publication of AU2018329047B2 publication Critical patent/AU2018329047B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2018329047A 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use Active AU2018329047B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710801364.3 2017-09-07
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE

Publications (2)

Publication Number Publication Date
AU2018329047A1 AU2018329047A1 (en) 2020-03-12
AU2018329047B2 true AU2018329047B2 (en) 2023-09-07

Family

ID=65634832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018329047A Active AU2018329047B2 (en) 2017-09-07 2018-09-07 Cycloolefin substituted heteroaromatic compounds and their use

Country Status (19)

Country Link
US (3) US11414390B2 (https=)
EP (1) EP3679020A4 (https=)
JP (2) JP7273030B6 (https=)
KR (1) KR102566237B1 (https=)
CN (6) CN109467538A (https=)
AR (1) AR112794A1 (https=)
AU (1) AU2018329047B2 (https=)
CA (1) CA3073782A1 (https=)
CL (1) CL2020000553A1 (https=)
EA (1) EA202090653A1 (https=)
IL (1) IL272923B2 (https=)
MX (1) MX2020002505A (https=)
PE (1) PE20200727A1 (https=)
PH (1) PH12020500408A1 (https=)
SG (1) SG11202001642WA (https=)
TW (1) TWI816693B (https=)
UA (1) UA129118C2 (https=)
WO (1) WO2019047909A1 (https=)
ZA (1) ZA202001448B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
CN116209655A (zh) * 2020-11-09 2023-06-02 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (zh) * 2022-01-11 2023-07-20 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2010151791A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AU2005247441A1 (en) 2004-05-24 2005-12-08 Equusys, Incorporated Animal instrumentation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2008031556A2 (en) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
EP2912024B1 (en) * 2012-10-24 2016-07-20 Basf Se Herbicidal azines
US9862692B2 (en) 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
MY185687A (en) * 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
AU2014342338B2 (en) 2013-11-01 2016-12-01 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
TWI722004B (zh) 2015-07-30 2021-03-21 大陸商正大天晴藥業集團股份有限公司 1,3,5-三嗪衍生物及其使用方法
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017096945A1 (zh) 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
HUE064145T2 (hu) 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
JP6557441B1 (ja) 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2010151791A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAIRD MARK S. ET AL.: "A simple route to 3-(dihalomethylene)cyclo-alkenes", TETRAHEDRON LETTERS, vol. 23, 31 December 1982 (1982-12-31), pages 3795 - 3796, XP055582077 *
BESSIÈRE-CHRÉTIEN Y. ET AL: "Ene syntheses in the s -triazine series", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 11, no. 3, 1 June 1974 (1974-06-01), US, pages 317 - 319, XP055788296, ISSN: 0022-152X, DOI: 10.1002/jhet.5570110309 *
CAS Registry Numbers 1993034-73-3 (Entered STN: 14 Sep 2016) and 1622560-40-0 (Entered STN: 12 Sep 2014) *
CAS Registry Numbers 2151236-51-8 (Entered STN: 05 Dec 2017), 2144351-79-9 (Entered STN: 20 Nov 2017), 2140125-40-0 (Entered STN: 09 Nov 2017) *
MARTINEZ A. G. ET AL.: "Fragmentation of vinyl triflates by electron impact. Mechanism of an unusual double hydrogen atom transfer reaction", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 8, 31 December 1994 (1994-12-31), pages 427-431 *

Also Published As

Publication number Publication date
BR112020004563A2 (pt) 2020-09-08
CN111132967B (zh) 2023-08-04
TW201912632A (zh) 2019-04-01
AU2018329047A1 (en) 2020-03-12
US20210363115A2 (en) 2021-11-25
JP7603740B2 (ja) 2024-12-20
CN117257809A (zh) 2023-12-22
JP7273030B6 (ja) 2024-02-15
PE20200727A1 (es) 2020-07-23
CL2020000553A1 (es) 2020-08-07
CN111132967A (zh) 2020-05-08
CN116999441A (zh) 2023-11-07
EP3679020A4 (en) 2021-05-05
UA129118C2 (uk) 2025-01-22
JP2020533319A (ja) 2020-11-19
US20250223267A1 (en) 2025-07-10
CN109467538A (zh) 2019-03-15
JP7273030B2 (ja) 2023-05-12
US11414390B2 (en) 2022-08-16
SG11202001642WA (en) 2020-03-30
EA202090653A1 (ru) 2021-02-03
KR102566237B1 (ko) 2023-08-14
PH12020500408A1 (en) 2021-03-01
CN117024363A (zh) 2023-11-10
US12234211B2 (en) 2025-02-25
IL272923A (en) 2020-04-30
TWI816693B (zh) 2023-10-01
IL272923B2 (en) 2023-06-01
CA3073782A1 (en) 2019-03-14
AR112794A1 (es) 2019-12-11
ZA202001448B (en) 2024-11-27
CN117797156A (zh) 2024-04-02
NZ762447A (en) 2023-09-29
JP2023103290A (ja) 2023-07-26
MX2020002505A (es) 2020-07-20
US20210163426A1 (en) 2021-06-03
EP3679020A1 (en) 2020-07-15
US20220372005A1 (en) 2022-11-24
WO2019047909A1 (en) 2019-03-14
KR20200052321A (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
TWI881008B (zh) 嗒基-噻唑甲醯胺化合物
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
JP2022081606A (ja) Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
AU2018329047B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
TW200838517A (en) Compounds useful as protein kinases inhibitors
CA3049175A1 (en) Jak1 selective inhibitors
CA3150284A1 (en) Aza-quinoline compounds and uses thereof
JP2025530793A (ja) Ｅｇｆｒ阻害剤及びその使用
NZ762447B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
EA044101B1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
TW202547473A (zh) 選擇性ｊａｋ２抑制劑及其用途
BR112020004563B1 (pt) Compostos heteroaromáticos substituídos por ciclo-olefina e seu uso
HK40097382A (zh) 环烯烃取代的杂芳环类化合物及其用途
WO2026026840A1 (en) Tricyclic compounds and uses thereof
HK40109090A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40098874A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40096142A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use
HK40077297B (zh) 氮杂-喹啉化合物及其用途
HK40077297A (en) Aza-quinoline compounds and uses thereof
HK40027076B (zh) 环烯烃取代的杂芳环类化合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)